logo
Plus   Neg
Share
Email

Harman International Industries Q3 Profit Surges - Quick Facts

Harman International Industries Inc (HAR) reported that its third-quarter net income was $172.66 million or $2.38 per share, up from $36.60 million or $0.51 per share in the same quarter last year. The company said that release of a deferred tax asset valuation allowance increases earnings per share by $1.71 to $2.38.

Non-GAAP earnings per share increased to $0.74 from $0.60 last year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.67 per share for the quarter. Analysts' estimates typically exclude special items.

Net sales for the quarter rose to $1.096 billion from $948.20 million in the prior year quarter. Two analysts had consensus revenue estimate of $1.04 billion for the quarter.

Harman International Industries also declared a cash dividend on April 30, 2012 of $.075 cents per share for the third quarter ended March 31, 2012. The quarterly dividend will be paid on May 24, 2012, to each stockholder of record as of the close of business on May 10, 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT